Spanish Breast Cancer Research Group

This study tested a combination of three drugs (trastuzumab, tucatinib, and vinorelbine) in 13 people with advanced HER2-positive breast cancer that could not be removed by surgery. The goal was to see if the treatment shrank tumors. The trial was ended early, so results are limi…

This study aimed to see if the drug trastuzumab deruxtecan (T-DXd) could help people with HER2-positive advanced or metastatic breast cancer whose cancer had stopped responding to standard first-line therapy. The plan was to treat 41 participants, but the trial was terminated ear…

This study looked at immune cells in the blood and tumor tissue of people with advanced breast cancer that has spread. The goal was to measure different types of natural immune cells and see how they relate to cancer progression. About 32 patients and 6 healthy volunteers provide…